Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to -$1.8 million.

  • Immucell's Free Cash Flow fell 14411.19% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $715351.0, marking a year-over-year increase of 20033.4%. This contributed to the annual value of -$107822.0 for FY2024, which is 9835.81% up from last year.
  • Latest data reveals that Immucell reported Free Cash Flow of -$1.8 million as of Q3 2025, which was down 14411.19% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Immucell's Free Cash Flow ranged from a high of $1.4 million in Q2 2025 and a low of -$3.4 million during Q1 2023
  • Moreover, its 5-year median value for Free Cash Flow was -$569832.0 (2022), whereas its average is -$680714.6.
  • In the last 5 years, Immucell's Free Cash Flow plummeted by 228901.21% in 2022 and then soared by 25754.4% in 2025.
  • Immucell's Free Cash Flow (Quarter) stood at -$116701.0 in 2021, then plummeted by 2289.01% to -$2.8 million in 2022, then surged by 71.15% to -$804415.0 in 2023, then skyrocketed by 75.23% to -$199267.0 in 2024, then crashed by 791.52% to -$1.8 million in 2025.
  • Its Free Cash Flow stands at -$1.8 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.2 million for Q1 2025.